Aprea Therapeutics, Inc.

Listed Company

APRECIK 0001781983NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-12.60M

Total Assets

$15.93M

Equity

$12.44M

Shares Out

11.45M

Op. Cash Flow

$-12.89M

Business

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology using synthetic lethality to selectively target cancer cells. It develops orally bioavailable small-molecule therapeutics, including a WEE1 inhibitor (APR-1051), an ATR inhibitor (ATRN-119), and an early-stage undisclosed DNA damage response (DDR) inhibitor, and previously-disclosed p53 reactivators. Key business activities are organized around discovery platforms (RepliBiom, ATRIZE™, SCET™), preclinical research and clinical-stage pipeline development. The company conducts clinical trials primarily in the United States and retains worldwide development and commercialization rights, using contract manufacturing and clinical site networks for distribution and supply.

Summary from filing dated 2025-03-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Grant revenue	285,759	2	583,231	—	—
Research and development	7	9	8	16	24
General and administrative	6	6	8	21	14
Total operating expenses	14	16	16	113	37
Loss from operations	−13	−14	−15	−113	−37
Interest income, net	652,086	1	1	448,667	1,648
Other income	77,500	—	—	—	—
Foreign currency (loss) gain	−95,319	71,800	−38,926	281,534	317,402
Total other income	634,267	1	1	730,201	319,050
Net loss	−13	−13	−14	−113	−37
Foreign currency translation	−7,335	−16,106	12,135	−264,452	−321,695
Total comprehensive loss	−13	−13	−14	−113	−37
Net loss per share attributable to common stockholders, basic (in dollars per share)	−1.93	−2.35	−3.95	−67.99	−34.88
Net loss per share attributable to common stockholders, diluted (in dollars per share)	−1.93	−2.35	−3.95	−67.99	−34.88
Weighted-average common shares outstanding, basic (in shares)	7	6	4	2	1
Weighted-average common shares outstanding, diluted (in shares)	7	6	4	2	1

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	15	23	22	29	53
Prepaid expenses and other current assets	961,899	726,254	914,275	1	4
Total current assets	16	24	23	30	57
Property and equipment, net	59,807	81,522	88,362	2,321	23,870
Restricted cash	41,186	40,170	40,717	—	—
Other noncurrent assets	271,162	281,662	—	—	29,372
Total assets	16	24	23	30	57
Accounts payable	713,668	1	2	842,754	2
Accrued expenses	2	2	2	2	5
Total current liabilities	3	3	4	3	7
Commitments and contingencies (Note 9)	—	—	—	—	—
Common stock, $0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	8,192	5,481	3,736	2,655	1,092
Additional paid-in capital	357	351	336	330	241
Accumulated other comprehensive loss	−11	−11	−11	−11	−10
Accumulated deficit	−334	−321	−308	−294	−181
Total stockholders' equity	12	19	17	26	50
Total liabilities and stockholders' equity	16	24	23	30	57

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−13	−13	−14	−113	−37
Depreciation and amortization	21,715	22,318	7,052	4,403	12,829
Stockbased compensation	478,141	489,436	444,459	17	8
Issuance of common stock to consultants	39,050	17,435	—	—	—
Prepaid expenses and other current and noncurrent assets	−217,906	−96,674	451,994	2	−109,338
Accounts payable	−646,701	−314,207	827,463	−858,513	−3
Accrued expenses	−64,488	−115,541	−189,720	−3	−5
Deferred grant revenue	—	−528,974	528,974	—	—
Net cash used in operating activities	−13	−14	−12	−25	−38
Purchases of property and equipment	—	−15,478	−93,093	—	—
Net cash used in investing activities	—	−15,478	−93,093	—	—
Proceeds from the exercise of warrants	91	—	—	—	—
Proceeds from issuance of common stock	5	16	6	682,973	2
Common stock issuance costs	−407,459	−1	−648,928	—	—
Net cash provided by financing activities	5	15	5	682,973	2
Change in cash, cash equivalents and restricted cash	−8	1	−7	−24	−36
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4,679	−7,181	−8,399	38,758	−2,467
Conversion of Series A convertible preferred stock to common stock	583,702	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro